| Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Endogenous Catecholamine   
| Agonist of α and β receptors; positive ionotropic (contractility) and chronotropic (rate) on heart (β1), vasoconstriction in vascular beds (α), and vasodilation in skeletal muscle blood vessels (β2) which may lower TPR | tachycardia, arrhythmia, anxiety, hypertension, and acute pulmonary edema | Cardiac arrest (increases cardiac output), anaphylaxis
 
 |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Endogenous catecholamine   
| Agonist of α1, α2, and β1 receptors but little effect on β2; increases TPR and BP, positive ionotropic effect on heart | Ischemia, arrhythmias | Hypotension, ADHD, depression |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Endogenous Catecholamine   
| Activates D1 receptors causing vasodilation of renal, splanchnic, coronary, cerebral, and other resistance vessels. Activation of D2 receptors suppresses norepinephrine release. Also activates β1receptors in heart and at high concentrations α receptors leading to vasoconstriction. Regulates Na+ secretion and renal function.  Neurotransmitter in the CNS and is involved in reward system of addiction. | Hypotension at high doses | Parkinson’s disease (caused by a deficiency of dopamine in basal ganglia); Dopamine receptors are targets for antipsychotic drugs |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Direct-Acting Sympathomimetic   
| α1 agonist; vasoconstriction = ↑ arterial resistance and ↓ venous capacity, ↑ stroke volume causes ↑ CO, ↑ BP may cause reflexive ↓ HR; α1 r’s also constrict pupillary dilator muscle | hypertension | Decongestant, mydriatic (dilates pupil), can be used to increase BP |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Direct-Acting Sympathomimetic   
| α2 agonist; cause vasoconstriction when given locally, but systemically acts through CNS to decrease sympathetic tone and BP | Dry mouth, sedation Drowsiness Impaired ejaculation | hypertension |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Direct-Acting Sympathomimetic   
| α agonist with affinity for α2A receptor; promotes vasoconstriction of nasal mucosa  | Hypotension (central Clonidine-like effect) | Topical decongestant |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Direct-Acting Sympathomimetic   
| Potent β1 and β2 agonist, positive chronotropic and ionotropic effects, vasodilator = ↑ CO, ↓ TPR and ↓ BP | Tachycardia, dysrhythmias | Bradycardia, heart block |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Direct-Acting Sympathomimetic   
| Β1 agonist; activate β1 receptors causing ↑ CO with less reflexive tachycardia because they do not activate vasodilator β2 receptors | Hypertension, arrhythmias  | Heart failure, cardiogenic shock |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Mixed-Acting Sympathomimetic   
| Indirect stimulation of the adrenergic receptor system by increasing the activity of noradrenaline at α- and β-receptors, ability to cross blood-brain barrier into CNS makes it a mild stimulant  | Tachycardia, arrhythmias, various nervous system symptoms | Ma huang (herbal medicine) decongestant, bronchodilator, weight loss |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Indirect-Acting Sympathomimetics   
| Acts as both a norepinephrine transporter (NET) substrate and reuptake blocker, eliciting reverse transport and blocking normal uptake = ↑ NE in synaptic cleft; release of NE and some dopamine; similar to ephedrine but enters CNS more readily | Elevates CO and BP CNS stimulation | Marked stimulant effect on mood and alertness and depressant effect on appetite |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Indirect-Acting Sympathomimetics   
| Pharmacologic effects and abuse potential are similar to amphetamine (p.141); Block NET-mediated NE reuptake and enhance NE signaling similar to cocaine (p. 133) ??? | Nervousness, drowsiness, insomnia | ADHD, narcolepsy |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Indirect-Acting Sympathomimetics   
| Inhibits both norepinephrine and dopamine transporters; increases interstitial concentrations not only of norepinephrine, dopamine, serotonin, and glutamate; decreases GABA levels | Increase in BP and HR | Improves wakefulness in narcolepsy and some other conditions |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Indirect-Acting Sympathomimetics   
| Indirect sympathomimetic action caused by release of stored catecholamines = action similar to NE; readily metabolized by MAO in liver = high first-pass effect | Increase in BP Hypertensive crisis | Patients treated with monoamine oxidase (MAO) inhibitors may have intensified Tyramine effect (must avoid Tyramine containing foods like cheese) |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Catecholamine Reuptake Inhibitor   
| Inhibits transmitter reuptake at noradrenergic synapses; enters CNS and inhibits dopamine reuptake into neurons in the “pleasure centers” of the brain | Tachycardia, hallucinations, paranoid delusions; overdoses cause tachyarrhythmias and a marked ↑ BP, which can be life-threatening. CNS stimulation | Heavily abused drug - produces amphetamine-like”psychological effects that is shorter lasting and more intense |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Dopamine Agonist   
| D1 agonist; activates adenylyl cyclase; causes vascular smooth muscle relaxation | hypotension, reflex tachycardia, ↑ intraocular pressure | hypertension |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs Dopamine Agonist   
| D2 agonists; inhibits adenylyl cyclase and interacts with other intracellular pathways; restores dopamine actions in the CNS | Orthostatic hypotension | Parkinson’s disease, prolactinemia |    |  | 
        |  |